Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate, quantity: 2.5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - neostigmine is indicated for:,? reversal of the effects of non-depolarising neuromuscular blocking agents.,? prophylaxis and treatment of post-operative intestinal atony and urinary retention.,? treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; hypromellose; polysorbate 80; pregelatinised maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Canada - English - Health Canada

nora pharma inc - hydroxychloroquine sulfate - tablet - 200mg - hydroxychloroquine sulfate 200mg - antimalarials

Canada - English - Health Canada

mint pharmaceuticals inc - hydroxychloroquine sulfate - tablet - 200mg - hydroxychloroquine sulfate 200mg - antimalarials

Canada - English - Health Canada

mylan pharmaceuticals ulc - hydroxychloroquine sulfate - tablet - 200mg - hydroxychloroquine sulfate 200mg - antimalarials

Canada - English - Health Canada

pharmascience inc - hydroxychloroquine sulfate - tablet - 200mg - hydroxychloroquine sulfate 200mg - antimalarials

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate; polysorbate 80; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg - hydroxychloroquine sulfate is indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax , p. malariae , p. ovale , and susceptible strains of p. falciparum . it is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.

United States - English - NLM (National Library of Medicine)

northstar rxllc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg - hydroxychloroquine sulfate is indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax, p. malariae , p. ovale , and susceptible strains of p. falciparum . it is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine 200 mg - hydroxychloroquine sulfate tablets, usp are indicated for the suppressive treatment and treatment of acute attacks of malaria due to plasmodium vivax , p. malariae , p. ovale , and susceptible strains of p. falciparum . hydroxychloroquine sulfate tablets, usp are also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis. use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children.